Headquartered in Plymouth Meeting, PA Fiscal year ends December NASDAQ: INO inovio.com
Inovio Pharmaceuticals is a biotechnology company focused on developing and commercializing DNA medicines to treat and protect people from HPV-related diseases, cancer, and infectious diseases. The company's platform consists of two components: precisely designed DNA plasmids (small circular DNA molecules that instruct the body's cells to produce specific disease-fighting proteins) and its proprietary investigational CELLECTRA delivery device, which delivers DNA medicines without requiring chemical adjuvants, lipid nanoparticles, or viral vectors. Inovio's most advanced candidate, INO-3107, targets Recurrent Respiratory Papillomatosis (RRP), a rare disease caused by HPV, and is currently under FDA BLA review with Orphan Drug and Breakthrough Therapy designations. The company also has VGX-3100, an investigational DNA immunotherapy for cervical dysplasia associated with HPV types 16 and 18, being developed in Greater China by partner ApolloBio. Inovio is also advancing next-generation DNA-Encoded Monoclonal Antibody (DMAb) and DNA-Encoded Protein (DPROT) programs targeting rare diseases including Hemophilia A, Fabry Disease, and Hypophosphatasia. Updated
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Alexion, DraftKings, Inovio, Netflix, Snowflake and more.
Friday's top analyst upgrades and downgrades included AngloGold Ashanti, Fisker, News Corp, QuantumScape, Williams-Sonoma, YETI and Zillow.
Inovio Pharmaceuticals shares soared on Monday after the company provided an update for its coronavirus vaccine candidate.
Chris Lange Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.
Chris Lange While COVID-19 pandemic is not its only target, that has been the main driver of the interest in Inovio Pharmaceuticals so far in 2020.
Jon C. Ogg Friday's top analyst upgrades and downgrades included Amazon.com, Broadcom, Boeing, DraftKings, eBay, Electronic Arts, Hilton Worldwide, iRobot, NetApp, Peloton Interactive and Tesla.
Inovio Pharmaceuticals has announced that it received $71 million in funding from the U.S. Department of Defense to support the production of its delivery device for the COVID-19 vaccine.
Chris Lange Thursday's top analyst upgrades and downgrades included Aerojet Rocketdyne, Avis Budget, Carnival, Chipotle Mexican Grill, Expedia, Home Depot, Lowe's, MGM Resorts, Stratasys, Square and Walmart.
Wednesday's top analyst upgrades and downgrades included Alphabet, Advanced Micro Devices, Corning, FireEye, Inovia Pharmaceuticals, Lululemon Athletica, Nike, Roku, Starbucks, Tyson Foods and Walmart.
Biotech firm Inovio has begun Phase 1 trials of a new vaccine for COVID-19. The trial is beginning Monday.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and here is where their stocks stand now.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this novel coronavirus. Here's how they fared as the week wound…
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Markets looked like they would be crushed yet again on Monday. 24/7 Wall St. has tracked some stocks that either are defensive in general or were defying Monday’s big drop.
Inovio Pharmaceuticals is a biotechnology company focused on developing and commercializing DNA medicines to treat and protect people from HPV-related diseases, cancer, and infectious diseases.
The Wall Street consensus 12-month price target for INO is $3.17.
